Acrivon Therapeutics Inc
ACRV1.280USD
+0.020+1.59%
Market hours （ET）Quotes delayed by 15 min
40.13MMarket Cap
LossP/E TTM
More Details of Acrivon Therapeutics Inc Company
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Company Info
Ticker SymbolACRV
Company nameAcrivon Therapeutics Inc
IPO dateNov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
Number of employees75
Security typeOrdinary Share
Fiscal year-endNov 15
Address480 Arsenal Way, Suite 100
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone16172078979
Websitehttps://acrivon.com/
Ticker SymbolACRV
IPO dateNov 15, 2022
CEODr. Peter Blume-Jensen, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Shareholder Types
Shareholders
Proportion
Venture Capital
26.60%
Hedge Fund
13.15%
Corporation
12.27%
Individual Investor
8.56%
Investment Advisor
7.97%
Investment Advisor/Hedge Fund
6.91%
Research Firm
0.36%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
24.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
142
23.71M
75.61%
-5.03M
2025Q1
146
29.35M
93.70%
-2.39M
2024Q4
141
30.19M
96.96%
-1.30M
2024Q3
129
30.21M
97.90%
-1.16M
2024Q2
124
30.86M
100.26%
+1.75M
2024Q1
110
20.99M
93.28%
+95.57K
2023Q4
96
21.08M
95.04%
+130.06K
2023Q3
91
21.13M
95.90%
+687.39K
2023Q2
85
20.62M
94.10%
+177.16K
2023Q1
71
22.16M
102.70%
+6.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
8.34M
26.6%
--
--
Mar 31, 2025
Chione, Ltd.
3.85M
12.27%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.21M
7.04%
-79.67K
-3.49%
May 21, 2025
Sands Capital Ventures LLC
2.12M
6.77%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.90M
6.05%
-224.13K
-10.57%
Mar 31, 2025
Wellington Management Company, LLP
888.13K
2.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
844.91K
2.69%
-5.84K
-0.69%
Mar 31, 2025
The Vanguard Group, Inc.
674.79K
2.15%
+3.17K
+0.47%
Mar 31, 2025
Marshall Wace LLP
450.39K
1.44%
-147.40K
-24.66%
Mar 31, 2025
Acorn Capital Advisors, LLC
405.24K
1.29%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
iShares Russell 2000 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
